The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy

AUTOR(ES)

Schülke, Norbert

FONTE

National Academy of Sciences

RESUMO

Prostate-specific membrane antigen (PSMA) is a type 2 integral membrane glycoprotein that serves as an attractive target for cancer immunotherapy by virtue of its abundant and restricted expression on the surface of prostate carcinomas and the neovasculature of most other solid tumors. However, relatively little is known about the molecular structure of this target. Here, we report that PSMA is expressed on tumor cells as a noncovalent homodimer. A truncated PSMA protein, lacking transmembrane and cytoplasmic domains, also formed homodimers, indicating that the extracellular domain is sufficient for dimerization. PSMA dimers but not monomers displayed a native conformation and possessed high-level carboxypeptidase activity. A unique dimer-specific epitope was identified by using one of a panel of novel mAbs. When used to immunize animals, dimer but not monomer elicited antibodies that efficiently recognized PSMA-expressing tumor cells. These findings on PSMA structure and biology may have important implications for active and passive immunotherapy of prostate and other cancers.

Documentos Relacionados

• Prostate-specific antigen in screening for prostate cancer.
• Urology: Prostate-Specific Antigen
• What is the prevalence of prostate cancer among men with low prostate-specific antigen levels?
• PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer
• Prostate-specific membrane antigen can promote in vivo osseous metastasis of prostate cancer cells in mice